Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joseph Patrick Nkolola, Ph.D.

Co-Author

This page shows the publications co-authored by Joseph Nkolola and Dan Barouch.
Connection Strength

8.543
  1. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol. 2014 Sep 01; 88(17):9538-52.
    View in: PubMed
    Score: 0.606
  2. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine. 2014 Apr 11; 32(18):2109-16.
    View in: PubMed
    Score: 0.592
  3. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol. 2010 Apr; 84(7):3270-9.
    View in: PubMed
    Score: 0.445
  4. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. 2021 08; 596(7872):423-427.
    View in: PubMed
    Score: 0.246
  5. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021 06 15; 325(23):2370-2380.
    View in: PubMed
    Score: 0.246
  6. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.245
  7. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.243
  8. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. J Virol. 2021 Mar 16.
    View in: PubMed
    Score: 0.242
  9. Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nat Commun. 2021 03 05; 12(1):1474.
    View in: PubMed
    Score: 0.241
  10. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb; 590(7844):E25.
    View in: PubMed
    Score: 0.240
  11. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J Virol. 2021 Jan 20.
    View in: PubMed
    Score: 0.239
  12. Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell. 2020 10 01; 183(1):185-196.e14.
    View in: PubMed
    Score: 0.234
  13. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 10; 586(7830):583-588.
    View in: PubMed
    Score: 0.231
  14. Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. Am J Reprod Immunol. 2020 10; 84(4):e13288.
    View in: PubMed
    Score: 0.230
  15. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 08 14; 369(6505):806-811.
    View in: PubMed
    Score: 0.228
  16. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 08 14; 369(6505):812-817.
    View in: PubMed
    Score: 0.228
  17. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070.
    View in: PubMed
    Score: 0.228
  18. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421.
    View in: PubMed
    Score: 0.224
  19. Lack of therapeutic efficacy of an antibody to a4ß7 in SIVmac251-infected rhesus macaques. Science. 2019 09 06; 365(6457):1029-1033.
    View in: PubMed
    Score: 0.217
  20. Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018 12; 564(7734):E8.
    View in: PubMed
    Score: 0.206
  21. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018; 13(11):e0205139.
    View in: PubMed
    Score: 0.205
  22. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018 11; 563(7731):360-364.
    View in: PubMed
    Score: 0.204
  23. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0.200
  24. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.200
  25. Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat Med. 2018 06; 24(6):721-723.
    View in: PubMed
    Score: 0.199
  26. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. J Virol. 2017 10 15; 91(20).
    View in: PubMed
    Score: 0.190
  27. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017 Sep 20; 9(408).
    View in: PubMed
    Score: 0.190
  28. Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun. 2017 06 05; 8:15740.
    View in: PubMed
    Score: 0.186
  29. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016 12 08; 540(7632):284-287.
    View in: PubMed
    Score: 0.179
  30. Vaccine protection against Zika virus from Brazil. Nature. 2016 08 25; 536(7617):474-8.
    View in: PubMed
    Score: 0.174
  31. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015 Jul 17; 349(6245):320-4.
    View in: PubMed
    Score: 0.163
  32. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol. 2015 Mar; 89(5):2507-19.
    View in: PubMed
    Score: 0.157
  33. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013 Nov 14; 503(7475):224-8.
    View in: PubMed
    Score: 0.145
  34. Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. Nat Biomed Eng. 2020 11; 4(11):1030-1043.
    View in: PubMed
    Score: 0.058
  35. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
    View in: PubMed
    Score: 0.058
  36. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020 04; 26(4):498-501.
    View in: PubMed
    Score: 0.056
  37. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
    View in: PubMed
    Score: 0.054
  38. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
    View in: PubMed
    Score: 0.052
  39. Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity. 2019 01 15; 50(1):241-252.e6.
    View in: PubMed
    Score: 0.052
  40. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.050
  41. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017 06 20; 46(6):1073-1088.e6.
    View in: PubMed
    Score: 0.047
  42. SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. . 2016 Mar 09; 19(3):323-35.
    View in: PubMed
    Score: 0.043
  43. Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One. 2014; 9(5):e97229.
    View in: PubMed
    Score: 0.038
  44. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):12111-6.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.